LPTXLEAP THERAPEUTICS, INC.

Nasdaq leaptx.com


$ 2.74 $ -0.07 (-2.49 %)    

Friday, 13-Sep-2024 15:59:54 EDT
QQQ $ 474.86 $ 2.12 (0.45 %)
DIA $ 414.87 $ 2.97 (0.72 %)
SPY $ 561.82 $ 2.92 (0.52 %)
TLT $ 100.40 $ 0.27 (0.27 %)
GLD $ 238.66 $ 2.35 (0.99 %)
$ 2.74
$ 2.78
$ 2.71 x 100
-- x --
$ 2.72 - $ 2.82
$ 1.24 - $ 5.00
38,984
na
107.52M
$ 1.43
nm
TBD
na
na ($ 0.00)
na
TBD na
How to Read 10-K & 10-Q Reports To View SEC Filing Reports, Please Register or Sign In
# Filing Date Period End Date Type Report Link
1 08-12-2024 06-30-2024 10-Q
2 05-13-2024 03-31-2024 10-Q
3 03-18-2024 12-31-2023 10-K
4 11-13-2023 09-30-2023 10-Q
5 08-14-2023 06-30-2023 10-Q
6 05-15-2023 03-31-2023 10-Q
7 03-24-2023 12-31-2022 10-K
8 11-14-2022 09-30-2022 10-Q
9 08-12-2022 06-30-2022 10-Q
10 05-13-2022 03-31-2022 10-Q
11 03-11-2022 12-31-2021 10-K
12 11-12-2021 09-30-2021 10-Q
13 08-13-2021 06-30-2021 10-Q
14 05-14-2021 03-31-2021 10-Q
15 03-12-2021 12-31-2020 10-K
16 11-12-2020 09-30-2020 10-Q
17 08-13-2020 06-30-2020 10-Q
18 05-14-2020 03-31-2020 10-Q
19 03-16-2020 12-31-2019 10-K
20 11-14-2019 09-30-2019 10-Q
21 08-09-2019 06-30-2019 10-Q
22 05-15-2019 03-31-2019 10-Q
23 04-01-2019 12-31-2018 10-K
24 11-09-2018 09-30-2018 10-Q
25 08-08-2018 06-30-2018 10-Q
26 05-11-2018 03-31-2018 10-Q
27 02-23-2018 12-31-2017 10-K
28 11-13-2017 09-30-2017 10-Q
29 08-11-2017 06-30-2017 10-Q
30 05-12-2017 03-31-2017 10-Q
31 03-31-2017 12-31-2016 10-K
Guide for Analyst Ratings To View Analyst Ratings, Please Register or Sign In
# Date Analyst Firm Upside/Downside Price Target Change Rating Change Current Rating

News

OPINIONS

 hc-wainwright--co-reiterates-buy-on-leap-therapeutics-maintains-55-price-target

HC Wainwright & Co. analyst Swayampakula Ramakanth reiterates Leap Therapeutics (NASDAQ:LPTX) with a Buy and maintains $...

 rodman--renshaw-initiates-coverage-on-leap-therapeutics-with-buy-rating-announces-price-target-of-8

Rodman & Renshaw analyst Tony Butler initiates coverage on Leap Therapeutics (NASDAQ:LPTX) with a Buy rating and announc...

 hc-wainwright--co-maintains-buy-on-leap-therapeutics-lowers-price-target-to-55

HC Wainwright & Co. analyst Swayampakula Ramakanth maintains Leap Therapeutics (NASDAQ:LPTX) with a Buy and lowers the p...

Core News & Articles

- SEC Filing

 baird-maintains-outperform-on-leap-therapeutics-lowers-price-target-to-9

Baird analyst Joel Beatty maintains Leap Therapeutics (NASDAQ:LPTX) with a Outperform and lowers the price target from $11 t...

 hc-wainwright--co-reiterates-buy-on-leap-therapeutics-maintains-7-price-target

HC Wainwright & Co. analyst Swayampakula Ramakanth reiterates Leap Therapeutics (NASDAQ:LPTX) with a Buy and maintains $...

 leap-therapeutics-q4-eps-046-beats-055-estimate-cash-balance-of-706m

Leap Therapeutics (NASDAQ:LPTX) reported quarterly losses of $(0.46) per share which beat the analyst consensus estimate of $(0...

 leap-therapeutics-to-present-new-data-from-part-a-of-the-defiance-study-of-dkn-01-plus-bevacizumab-and-chemotherapy-in-colorectal-cancer-patients-at-the-2024-asco-gastrointestinal-cancers-symposium

Leap Therapeutics, Inc. (NASDAQ:LPTX), a biotechnology company focused on developing targeted and immuno-oncology therapeutics,...

 why-flj-group-shares-are-trading-higher-by-around-96-here-are-other-stocks-moving-in-fridays-mid-day-session

Shares of FLJ Group Limited (NASDAQ: FLJ) shares jumped during Friday’s session after the company announced it entered into a d...

 mizuho-maintains-buy-on-leap-therapeutics-lowers-price-target-to-12

Mizuho analyst Mara Goldstein maintains Leap Therapeutics (NASDAQ:LPTX) with a Buy and lowers the price target from $20 to $12.

CLASS ACTION DEADLINES - JOIN NOW!

NEW CASE INVESTIGATION